

Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab

Guido Lancman,^{1,2} Dahniel Sastow,³ Minira Aslanova,³ Erin Moshier,⁴ Hearn Jay Cho,¹ Sundar Jagannath,¹ Samir Parekh,¹ Shambavi Richard,¹ Joshua Richter,¹ Cesar Rodriguez,¹ Adriana Rossi,¹ Larysa Sanchez,¹ Santiago Thibaud¹ and Ajai Chari^{1,5}

¹Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ²Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; ³Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁴Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA and ⁵Department of Hematology and Medical Oncology, University of California San Francisco, San Francisco, CA, USA

Correspondence: Guido Lancman
guido.lancman@uhn.ca

Received: September 16, 2025.
Accepted: April 3, 2026.
Early view: April 23, 2026.

<https://doi.org/10.3324/haematol.2025.289215>

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license 

Supplementary Table 1: Multivariable Cox Regression comparing IVIG group and reference group

Variable	Adjusted HR	95% CI	P-value
Age (per 5 yr)	1.17	0.95-1.44	0.140
Years dx to dara (per 5 yr)	1.59	0.81-3.14	0.179
lines_of_therapy	0.84	0.66-1.07	0.167
numinfections	1.88	1.42-2.48	<0.001
Sex: Female	1.14	0.52-2.51	0.744
Heavy chain: IgG	0.24	0.10-0.59	0.002
Heavy chain: IgA	0.38	0.13-1.15	0.088
Heavy chain: IgD	6.22	0.49-78.43	0.157
Heavy chain: IgE	NA	NA-NA	NA
Heavy chain: IgM	NA	NA-NA	NA
Light chain: Kappa	1.50	0.61-3.65	0.378
Light chain: Both	NA	NA-NA	NA
ISS: II	1.95	0.76-4.98	0.162
ISS: III	1.99	0.80-4.98	0.140
High-risk cyto: Yes	1.01	0.44-2.32	0.974
HGG baseline: Yes	1.83	0.66-5.02	0.244

Reference groups: Sex=Male, Heavy chain=None (light chain only), Light chain=Lambda, ISS=I, High-risk cyto=No, HGG=No